Drugs / Zhibitai
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06822946 Comparator | Mar 2025 → Feb 2026 overdue | hyperlipoproteinemia | Chengdu Diao Jiuhong Pharmaceutical Factory | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zhibitai | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06822946 ↗ |
| Route | Oral | “2 capsule of Zhibitai capsule/time, 2 times/day, oral” NCT06822946 ↗ |